Cognition Therapeutics Inc (NAS:CGTX)

$ 0.84 0.0726 (9.46%) Market Cap: 34.90 Mil Enterprise Value: 10.45 Mil PE Ratio: 0 PB Ratio: 2.37 GF Score: 28/100

Q2 2024 Cognition Therapeutics Inc Earnings Call Transcript
Aug 08, 2024

$0.5847 (+0.46%)

Earnings
Q4 2023 Cognition Therapeutics Inc Earnings Call Transcript
Mar 26, 2024

$1.83 (+0.55%)

Earnings
Q2 2023 Cognition Therapeutics Inc Earnings Call Transcript
Aug 08, 2023

$1.72 (-0.86%)

Earnings
Cognition Therapeutics Inc to Discuss Topline Results From Phase 2 Sequel Clinical Update Call Transcript
Jun 28, 2023
Q4 2022 Cognition Therapeutics Inc Earnings Call Transcript
Mar 23, 2023

$1.83 (-1.61%)

Earnings
Cognition Therapeutics Inc at JMP Securities Life Sciences Conference Transcript
Jun 16, 2022
Cognition Therapeutics, Inc. - Special Call Transcript
Jun 09, 2022
Cognition Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 11, 2022
Q4 2021 Cognition Therapeutics Inc Earnings Call Transcript
Mar 30, 2022

$2.66 (-10.44%)

Earnings

Cognition Therapeutics Inc to Discuss Topline Results From Phase 2 Sequel Clinical Update Call Transcript

Jun 28, 2023 / 12:00PM GMT

Release Date Price: $2.18 (-12.80%)

Transcript

Operator

Good morning, ladies and gentlemen, and welcome to Cognition Therapeutics Sequel Study Clinical Update Conference Call and Webcast. My name is Sarah, and I will be your conference operator today. This call is being recorded. I would like to turn the presentation over now to your host for today's call -- sorry, Mr. Daniel Kontoh-Boateng, Investor Relations for Cognition Therapeutics. Please proceed, Mr. Kontoh-Boateng.

Daniel Kontoh;Boateng

Good morning, and thank you for participating in Cognition Therapeutics conference call and webcast today. With me today are Lisa Ricciardi, President and Chief Executive Officer of Cognition; Anthony Caggiano, Chief Medical Officer and Head of R&D of Cognition and Willem de Haan, neurologist and senior researcher of Amsterdam University Medical Center.

A press release of the company's Phase II SEQUEL study results is available in the Investors section of the company's investor website. In addition, this conference call is being webcast through the company's website and will be archived for 90 days.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.